<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medtronic</title>
	<atom:link href="http://www.stockbloghub.com/tag/medtronic/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MDT) Top Health Equity Mutual Funds</title>
		<link>http://www.stockbloghub.com/2009/09/02/mdt-top-health-equity-mutual-funds/14159</link>
		<comments>http://www.stockbloghub.com/2009/09/02/mdt-top-health-equity-mutual-funds/14159#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:21:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Incorporated]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14159</guid>
		<description><![CDATA[Today we are featuring top-performing “Health&#8221; equity mutual funds, which primarily invest in equity securities of health care and related companies. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds. 3 Robust Samples Fidelity Select Medical Equipment &#38; Systems (FSMEX) seeks capital appreciation. The fund is non-diversified. The fund invests in common stocks of firms that are engaged in research, development, manufacture, distribution, supply or sale of medical equipment and devices and related technologies. It may invest in securities of foreign issuers or a significant percentage of assets in a single issuer. The fund’s key holdings include Medtronic Inc. (MDT), Baxter International Inc. (BAX) and Boston Scientific Inc. (BSX). Evergreen Health Care A (EHABX) was incepted in December 1999. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/mdt-top-health-equity-mutual-funds/14159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Positive Drug Trial Results for Medtronic</title>
		<link>http://www.stockbloghub.com/2009/08/31/mdt-positive-drug-trial-results-for-medtronic/13919</link>
		<comments>http://www.stockbloghub.com/2009/08/31/mdt-positive-drug-trial-results-for-medtronic/13919#comments</comments>
		<pubDate>Mon, 31 Aug 2009 16:10:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Incorporated]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13919</guid>
		<description><![CDATA[Medtronic, Inc. (MDT) announced positive results from its REVERSE trial, which was designed to evaluate the effectiveness of cardiac resynchronization therapy (CRT) in mildly symptomatic or asymptomatic patients &#8212; that is, those with mild heart failure or patients who previously had heart failure symptoms, respectively. The trial enrolled 610 patients and the 24-month data was presented from the European cohort of the study. Initial results for the 12-month period presented earlier were disappointing &#8212; the trial failed to meet statistical significance in its primary endpoint. However, the 24-month data proved successful in meeting the end points. At present, CRT is not approved in the U.S. for the treatment of symptomatic or asymptomatic patients. It is used only for patients with moderate to severe heart failure. The major findings in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/mdt-positive-drug-trial-results-for-medtronic/13919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Gets FDA Approval</title>
		<link>http://www.stockbloghub.com/2009/08/28/atsi-ats-medical-gets-fda-approval/13831</link>
		<comments>http://www.stockbloghub.com/2009/08/28/atsi-ats-medical-gets-fda-approval/13831#comments</comments>
		<pubDate>Fri, 28 Aug 2009 22:49:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corp]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13831</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) has received approval from the U.S. Food and Drug Administration (FDA) for a landmark clinical study in which cardiac surgeons will implant the company’s ATS 3f Aortic Bioprosthesis valve in a younger aortic valve replacement patient population. The clinical study will be performed to evaluate the effectiveness of ATS 3f Aortic Bioprosthesis valve in a younger population, those less than 60 years of age. The ATS 3f is a tissue valve that functions like a natural valve. It has the same tube shape that helps in maintaining a steady blood flow at a normal speed. Valves are subject to natural wear and tear. The 3f valve is used for replacing a valve in the aorta, the largest blood vessel in the body. ATS Medical is looking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/atsi-ats-medical-gets-fda-approval/13831/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Earnings Preview for Medtronic</title>
		<link>http://www.stockbloghub.com/2009/08/25/mdt-earnings-preview-for-medtronic/13281</link>
		<comments>http://www.stockbloghub.com/2009/08/25/mdt-earnings-preview-for-medtronic/13281#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:10:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Incorporated]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13281</guid>
		<description><![CDATA[Medtronic, Inc. (MDT) will report its fiscal first quarter results tomorrow before the market opens. The Zacks Consensus Estimate for the current quarter is pegged at 78 cents per share. Revenues are estimated at $3.82 billion. Stability in the company’s two leading segments – heart and spinal devices – is expected in the first quarter. The company suffered major setbacks in these segments. Medtronic has lost market share of implantable cardiac defibrillators (ICDs) to rivals Boston Scientific Corp. (BSX) and St. Jude Medical (STJ) in 2009. The company also recalled roughly 37,000 pacemakers due to manufacturing defects. The company is looking to reduce headcount following the dismal last quarter earnings, which declined roughly 69% on lower sales, restructuring and other charges. It expects to reduce its headcount for a maximum ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/mdt-earnings-preview-for-medtronic/13281/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Meets Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2009/08/25/mdt-medtronic-meets-earnings-expectations/13333</link>
		<comments>http://www.stockbloghub.com/2009/08/25/mdt-medtronic-meets-earnings-expectations/13333#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:03:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Incorporated]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13333</guid>
		<description><![CDATA[Medtronic, Inc. (MDT) reported results for the first quarter of fiscal 2010. Earnings per share were 79 cents, higher than the Zacks Consensus Estimate of 78 cents and the year-ago earnings per share of 72 cents. Sales Net sales in the quarter were $3.933 billion Incorporatedreasing 6% year over year. Excluding the impact of a strong U.S. dollar, net sales increased 10% year over year. Growth was witnessed across all seven operating segments – both on a reported and constant-currency basis. Cardiac Rhythm Disease Management (CRDM) revenues increased approximately 3% year over year to $1.337 billion. Growth was fueled by strong demand for pacemakers and implantable cardiac defibrillators (ICDs) that increased roughly 2% and 1% year over year, respectively. We believe the company will continue to maintain its strong position ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/mdt-medtronic-meets-earnings-expectations/13333/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Launches New Device</title>
		<link>http://www.stockbloghub.com/2009/08/14/mdt-medtronic-launches-new-device/12531</link>
		<comments>http://www.stockbloghub.com/2009/08/14/mdt-medtronic-launches-new-device/12531#comments</comments>
		<pubDate>Fri, 14 Aug 2009 23:44:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12531</guid>
		<description><![CDATA[Medtronic Inc. (MDT) recently launched a new vertebral body replacement device, T2 SCEPTOR Distractible End Cleats System, for the replacement of a collapsed, damaged or unstable vertebra. The product is used in the thoracic and lumbar spine region (T1-L5) of the body in combination with PYRAMESH C Surgical Titanium centerpieces and additional anterior and/or posterior spinal instrumentation to augment stability. Approval of the new device should strengthen Medtronic’s position in the spine market. The company is a global leader in medical technology, specializing in implantable and interventional therapy devices and products. It is a market leader in cardiology and spine devices that benefit from scale, resources and incremental sales synergies within the medical devices industry. Medtronic has a deep product pipeline and a strong R&#38;D program that positions it for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/14/mdt-medtronic-launches-new-device/12531/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

